Copper and many of its alloys (such as brasses, bronzes and copper-nickels) are inherently antimicrobial. With no surface treatment or additional processing, they will naturally kill bacteria, viruses and fungi that settle on their surfaces.
With their efficacy demonstrated in situ by clinical trials in countries around the world – and initial results from a three-centre US trial showing a greater than 40% reduction in patients’ risk of acquiring hospital infections in rooms with just six key copper touch surfaces – interest in and demand for these products is rising, and installations have begun within the NHS.
CDA is facilitating networking between all elements of the supply chain – from material suppliers to product manufacturers to solution providers – to facilitate procurement of products.
Professor Tom Elliott – leader of the pioneering UK clinical trial of copper and copper alloy surfaces that demonstrated a 90-100% reduction in contamination over standard surfaces – will present the latest clinical findings showing reduced infection rates observed in copper installations, driving demand for antimicrobial copper components.
Demand-side requirements for the UK and Europe will be described by speakers, including CDA and NHS Supply Chain, conveying the current needs of the health service and highlighting opportunities for manufacturers.
Interested parties are invited to email bryony.samuel@copperalliance.org.uk for further details and to book a free place.